Breathe Easy

An innovation in the management of severe equine asthma.

IMPORTANT SAFETY INFORMATION: ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares. In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing and nasal irritation/bleeding. Not for use in humans. Keep this and all medications out of the reach of children.

2_01 Home Page Introducing

A different way to manage the clinical signs of severe equine asthma

Horses with severe equine asthma struggle to breathe, even at rest. ASERVO EQUIHALER, our unique breathing treatment for horses, generates a slow-moving Soft MistTM that is easy to inhale, delivering medication deep into the lung. The most common adverse reactions reported in a large clinical field study were coughing, nasal discharge, sneezing and nasal irritation/bleeding. ASERVO EQUIHALER is not for human use.

2_01 Home Page Designed for Horses US Home Page

Designed for horses with severe asthma

The ASERVO EQUIHALER is designed specifically for use in horses with severe equine asthma. An ergonomic handle and dosing lever make it simple to administer. The anatomically designed nostril adaptor fits inside the nostril of the horse, making it easier for them to inhale the medicated mist. After veterinary consultation, please read and understand the entire contents of the user manual for instructions regarding proper handling and use of ASERVO EQUIHALER. Do not use in horses with known hypersensitivity to ciclesonide or glucocorticoids. 

ASERVO EQUIHALER delivers a novel glucocorticoid deep into the lung

Ciclesonide is a pro-drug that is activated in the airway epithelium to des-ciclesonide. The drug is delivered deep into the lung by the advanced Soft MistTM Technology, which creates a medical mist. ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares. Do not use in horses with known hypersensitivity to ciclesonide or glucocorticoids. 

Treat With
Confidence

Studied in Over

0

Horses*

Horses with severe equine asthma treated with ASERVO EQUIHALER demonstrated improved lung function and clinical signs and a reduced risk of the side effects often associated with cortisol suppression secondary to administration of other glucocorticoids.1 Concurrent use of other anti-inflammatory drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs) or other glucocorticoids, should be approached with caution.

*Treated with ASERVO EQUIHALER or placebo.

For more information about the ASERVO EQUIHALER, contact a Boehringer Ingelheim representative.

IMPORTANT SAFETY INFORMATION: ASERVO EQUIHALER has not been evaluated in pregnant or lactating mares. In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing and nasal irritation/bleeding. Administration of glucocorticoids may worsen existing bacterial, fungal, or viral infection and may induce the first stage of parturition. Glucocorticoids should be used with caution in horses at a higher risk for laminitis. Not for use in humans. Keep this and all medications out of the reach of children. In case of accidental inhalation, seek medical advice immediately. INFORMATION FOR HORSE OWNERS: After veterinary consultation, please read and understand the entire contents of the user manual for instructions regarding proper handling and use of ASERVO EQUIHALER.